论文部分内容阅读
目的:探讨罗格列酮的抗炎、抗动脉粥样硬化作用及其机制。方法:2型糖尿病合并冠心病患者60例随机分为罗格列酮治疗组和常规治疗组。采用酶联免疫吸附法测定血清基质金属蛋白酶-9、高敏C-反应蛋白水平,观察罗格列酮治疗前后血清基质金属蛋白酶-9、高敏C-反应蛋白水平变化及与常规治疗组之间变化的差别。结果:治疗2周时的血清基质金属蛋白酶-9、高敏C-反应蛋白水平分别较治疗前水平下降,应用罗格列酮治疗组较常规治疗组下降明显,差异有统计学意义(P<0.05)。空腹血糖在2治疗组间差异无统计学意义(P>0.05)。罗格列酮治疗12周时的血清基质金属蛋白酶-9、高敏C-反应蛋白较治疗2周时下降,差异有统计学意义(P<0.05)。结论:罗格列酮具有抗炎及独立于降糖之外的抗动脉粥样硬化作用,且在一定时期内具有时间依赖性。
Objective: To investigate the anti-inflammatory and anti-atherosclerotic effects of rosiglitazone and its mechanism. Methods: Sixty patients with type 2 diabetes mellitus complicated with coronary heart disease were randomly divided into rosiglitazone group and conventional treatment group. Serum levels of MMP-9 and high-sensitivity C-reactive protein were measured by enzyme-linked immunosorbent assay. Changes of serum MMP-9 and high-sensitivity C-reactive protein before and after rosiglitazone treatment were observed, The difference. Results: Serum levels of MMP-9 and Hypersensitive C-reactive protein decreased at 2 weeks after treatment, respectively. The levels of serum MMP-9 and Hyperoxia-C were lower than those before treatment. The treatment with rosiglitazone significantly decreased compared with the conventional treatment group (P <0.05 ). There was no significant difference in fasting blood glucose between the two treatment groups (P> 0.05). Rosiglitazone treatment at 12 weeks serum MMP-9, high-sensitivity C-reactive protein decreased compared to 2 weeks after treatment, the difference was statistically significant (P <0.05). CONCLUSIONS: Rosiglitazone possesses anti-atherogenic and atherosclerosis independent of hypoglycemic activity and is time-dependent over a period of time.